Didactics-Uterine Serous Carcinoma

Video Transcription

Video Summary

The presentation discusses uterine serous carcinoma and the evolving landscape of endometrial cancer classification, prompted by the 2013 Cancer Genome Atlas. It identifies four molecular subgroups that influence prognosis and treatment strategies. These involve surrogate markers for classification, with advanced molecular techniques becoming more accessible. Recent guidelines integrate these molecular insights into risk group classifications, crucial for managing patients, especially since most endometrial cancer cases currently have good prognoses. Changes in FIGO staging now incorporate molecular information, emphasizing the significance of ER status. The presentation also highlights disparities, such as higher carcinosarcoma incidence in non-Hispanic Black populations, potentially linked to specific p53 mutations. Treatment strategies emphasize the combination of chemotherapy and radiotherapy. The session raises questions about the accessibility of molecular markers and the role of adjuvant therapies, highlighting the complexity and molecular underpinnings of endometrial cancer as critical elements for future treatment decisions.

Asset Subtitle

Radiation Oncology ECHO discussion by Remi Nout
March 2025

Keywords

uterine serous carcinoma

endometrial cancer classification

molecular subgroups

p53 mutations

treatment strategies